Ascend Laboratories, Llc C/O UPS Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Ascend Laboratories, Llc C/O UPS Pharmaceutical Import Records from India — 2 Products, $850.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ascend Laboratories, Llc C/O UPS — Pharmaceutical Importer Profile (2026) | 2 Products, $850.0K Trade | TransData Nexus

Ascend Laboratories, Llc C/O UPS

Pharmaceutical Importer · United States · Advanced Antibiotics Focus · $850.0K Total Trade · DGFT Verified

Ascend Laboratories, Llc C/O UPS is a pharmaceutical importer based in United States with a total trade value of $850.0K across 2 products in 2 therapeutic categories. Based on 17 verified import shipments from Indian Customs (DGFT) records, Ascend Laboratories, Llc C/O UPS is the #1 buyer in 1 product including Cephalexin. Ascend Laboratories, Llc C/O UPS sources from 1 verified Indian supplier, with Alkem Laboratories Limited accounting for 100.0% of imports.

Ascend Laboratories, Llc C/O UPS — Import Portfolio & Supplier Network

Ascend Laboratories, Llc C/O UPS import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Ascend Laboratories, Llc C/O UPS?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Alkem Laboratories Limited	$257.1K	7	100.0%

Ascend Laboratories, Llc C/O UPS sources from 1 verified Indian supplier across 5 distinct formulations. The sourcing is highly concentrated — Alkem Laboratories Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

Formulation	Value	Ships
Pharmaceutical products cholestyramine fos USP f1(p)60s pouch ndc no67877029860each pouch contains 4 grames	$59.5K	3
Pharmaceutical products:cephalexin 500mgcaps(500s)anda ndc no67877021905 Each capsules contains:cephalexin	$50.0K	1
Pharmaceutical products:cephalexin 500mgcaps (100s)anda ndc no67877021901 eachcapsules contains: cephalexin	$50.0K	1
Pharmaceutical products cefuroxime axetil tabs USP 500MG 60s ndc no67877021660 Each tablet contains:cefuroxime axetil	$50.0K	1
Pharmaceutical products tamsulosin hcl 0.4MG CAPS USP(500s)usa ndc no67877045005each capsule contains:tamsulosin	$47.6K	1

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Linezolid	Advanced Antibiotics	$750.0K	15	2.0%	12
2	Cephalexin	Antibiotics	$100.0K	2	0.0%	1

Ascend Laboratories, Llc C/O UPS imports 2 pharmaceutical products across 2 categories into United States totaling $850.0K. The company is the #1 buyer for 1 product: Cephalexin.

Ascend Laboratories, Llc C/O UPS — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Ascend Laboratories, LLC, headquartered in Parsippany, New Jersey, is a dynamic pharmaceutical company specializing in the development and marketing of generic medications. Established in the early 2000s, Ascend initially focused on product development, assisting various companies in bringing off-patent medicines to market as generics. Over time, the company expanded its capabilities by acquiring sales and marketing operations, enabling it to obtain FDA approvals and launch products under its own label. By 2008, Ascend introduced its first three products to the market.

In 2014, Ascend Laboratories became a wholly owned subsidiary of ThePharmaNetwork, LLC, which is itself a subsidiary of S & B Holdings S.a.r.l., a wholly owned subsidiary of Alkem Laboratories Limited, a leading Indian pharmaceutical company. This strategic acquisition provided Ascend with access to Alkem's extensive research and development resources, advanced manufacturing capabilities, and a robust international supply chain, thereby enhancing its position in the U.S. pharmaceutical market.

Ascend Laboratories offers a diverse portfolio of over 300 stock-keeping units (SKUs) across various therapeutic categories, supplying hospitals, pharmacies, and wholesalers nationwide. The company's product range includes solid oral dosage forms, creams, ointments, powders, nasal sprays, and tablets, reflecting its commitment to improving patient access to essential medicines through innovation and strategic partnerships.

2Distribution Network

Ascend Laboratories operates its primary distribution center from Parsippany, New Jersey, strategically located to serve the U.S. market efficiently. While specific details about additional warehouse locations and logistics capabilities are not publicly disclosed, the company's affiliation with Alkem Laboratories Limited suggests access to a global supply chain network. This connection likely facilitates the importation of pharmaceutical products from various international markets, including India, to meet the diverse needs of the U.S. healthcare system.

3Industry Role

In the U.S. pharmaceutical supply chain, Ascend Laboratories functions primarily as a pharmaceutical importer and distributor. By sourcing generic medications from international markets, including India, and marketing them under its own label, Ascend plays a crucial role in enhancing the availability of affordable medications. The company's operations encompass product development, regulatory compliance, and distribution, positioning it as a key player in the generic pharmaceutical sector.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Ascend Laboratories, Llc C/O UPS

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Ascend Laboratories' sourcing strategy exhibits a high degree of concentration, with a significant portion of its imported pharmaceutical products originating from a single supplier, Alkem Laboratories Limited. This single-source dependency may present risks related to supply chain disruptions, such as production delays or quality control issues. However, the consistent volume of shipments and the strategic partnership with Alkem suggest a stable and reliable relationship, potentially mitigating some of these risks. The company's focus on a limited number of suppliers may also allow for more streamlined operations and stronger collaboration on product development and quality assurance.

2Supply Chain Resilience

The resilience of Ascend Laboratories' supply chain is closely tied to its relationship with Alkem Laboratories Limited. While the company imports finished pharmaceutical formulations from India, the lack of publicly available information on backup suppliers and the diversity of imported formulations makes it challenging to fully assess supply chain robustness. The strategic partnership with Alkem, a leading pharmaceutical manufacturer, likely ensures adherence to Good Manufacturing Practices (GMP) and regulatory compliance, contributing to the overall reliability of the supply chain.

Strategic Implications

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and marketing of pharmaceutical products. The Federal Food, Drug, and Cosmetic Act (FD&C Act) provides the legal framework governing the importation of drugs, ensuring they meet standards for safety, efficacy, and quality. Pharmaceutical companies must comply with FDA regulations, including facility registration, drug listing, and adherence to Good Manufacturing Practices (GMP), to obtain marketing authorization for their products.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the U.S. include the registration of foreign drug establishments with the FDA and the listing of all drug products intended for importation. Manufacturers must comply with FDA's GMP standards, which may involve recognition of certifications such as EU GMP, WHO GMP, or PIC/S. Additionally, wholesale distribution authorization is required for entities involved in the distribution of pharmaceutical products within the U.S. market.

3Quality & Labeling

Ascend Laboratories, Llc C/O UPS — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Ascend Laboratories' focus on importing advanced antibiotics and antibiotics aligns with the ongoing demand for effective treatments against bacterial infections in the U.S. market. The substantial import value of linezolid, a potent antibiotic, indicates a strategic emphasis on high-demand, high-value products. The company's product strategy reflects a commitment to addressing critical healthcare needs through the provision of essential medications.

2Sourcing Profile

Ascend Laboratories' sourcing strategy centers on importing finished pharmaceutical formulations from India, particularly in the antibiotic category. This approach leverages India's robust pharmaceutical manufacturing capabilities and cost advantages. The company's focus on finished products allows for quicker market entry and compliance with U.S. regulatory standards, as opposed to sourcing raw active pharmaceutical ingredients (APIs).

3Market Positioning

Based on its product mix, Ascend Laboratories serves various segments of the U.S. pharmaceutical market, including retail pharmacies, hospitals, and wholesalers. The company's emphasis on advanced antibiotics and antibiotics positions it to meet the needs of healthcare providers and patients requiring effective treatments for bacterial infections. Ascend's strategic partnerships and focus on generic medications enable it to offer cost-effective solutions across these market segments.

Seller's Guide — How to Become a Supplier to Ascend Laboratories, Llc C/O UPS

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Ascend Laboratories, given the company's focus on importing finished pharmaceutical formulations. Potential gaps in Ascend's current sourcing may include diversification of product offerings and the inclusion of additional therapeutic categories. Indian exporters can explore these opportunities by aligning their product portfolios with Ascend's strategic focus and ensuring compliance with FDA regulations.

2Requirements & Qualifications

Indian exporters seeking to supply Ascend Laboratories and the U.S. market must obtain FDA approval for their pharmaceutical products, which involves facility registration, drug listing, and adherence to GMP standards. Recognized certifications such as EU GMP, WHO GMP, or PIC/S can facilitate the approval process. Additionally, compliance with FDA labeling requirements, including the use of the English language and inclusion of all necessary information, is essential.

3How to Approach

Frequently Asked Questions — Ascend Laboratories, Llc C/O UPS

What products does Ascend Laboratories, Llc C/O UPS import from India?

Ascend Laboratories, Llc C/O UPS imports 2 pharmaceutical products across 2 categories. Top imports: Linezolid ($750.0K), Cephalexin ($100.0K).

Who supplies pharmaceuticals to Ascend Laboratories, Llc C/O UPS from India?

Ascend Laboratories, Llc C/O UPS sources from 1 verified Indian suppliers. The primary supplier is Alkem Laboratories Limited (100.0% of imports, $257.1K).

What is Ascend Laboratories, Llc C/O UPS's total pharmaceutical import value?

Ascend Laboratories, Llc C/O UPS's total pharmaceutical import value from India is $850.0K, based on 17 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Ascend Laboratories, Llc C/O UPS focus on?

Ascend Laboratories, Llc C/O UPS imports across 2 categories. The largest: Advanced Antibiotics (88.2%), Antibiotics (11.8%).

Get Full Ascend Laboratories, Llc C/O UPS Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.